Assessment of MRI scans of the brain after HDIT
. | Change in T2 burden of disease-blinded analyses . | . | Serial clinical assessment for new or enhancing lesions . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Baseline* . | Last follow-up (mo) . | Baseline† . | 1 mo‡ . | 3 mo . | 6 mo . | 12 mo . | 24 mo . | ||||||
| 1 | Severe | Stable (24) | 0 | NT | 0 | 0 | 0 | 0 | ||||||
| 2 | Mild | Stable (24) | 0 | NT | 0 | 0 | 0 | 0 | ||||||
| 3 | Mild | Stable (24) | 0 | NT | 0 | 0 | 0 | 0 | ||||||
| 4 | Moderate | Decreased (24) | E | E(2) | 0 | 0 | 0 | 0 | ||||||
| 5 | Mild | Stable (12) | E | 0 | 0 | 0 | 0 | NT | ||||||
| 6 | Moderate | Decreased (24) | E | 0 | 0 | 0 | E(1) | 0 | ||||||
| 7 | Moderate | Stable (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 8§ | Moderate | Stable (12) | 0 | 0 | 0 | NT | 0 | NT | ||||||
| 9∥ | ||||||||||||||
| 10 | Mild | Stable (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 11 | Moderate | Decreased (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 12 | Moderate | Stable (24) | E | 0 | E(1) | E(1) | 0 | 0 | ||||||
| 13 | Moderate | Stable (24) | 0 | NT | 0 | 0 | 0 | 0 | ||||||
| 14 | Mild | Decreased (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 15¶ | Mild | Stable (12) | 0 | 0 | 0 | 0 | 0 | NT | ||||||
| 16∥ | Moderate | Stable (12) | 0 | NT | 0 | NT | 0 | NT | ||||||
| 17 | Severe | Decreased (24) | 0 | 0 | 0 | NT | 0 | 0 | ||||||
| 18 | Moderate | Stable (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 19 | Moderate | Decreased (24) | E | 0 | NT | 0 | 0 | 0 | ||||||
| 20 | Mild | Increased (24) | E | 0 | 0 | 0 | 0 | 0 | ||||||
| 21 | Moderate | Stable (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 22 | Mild | Decreased (12) | 0 | 0 | 0 | 0 | 0 | — | ||||||
| 23 | Mild | Stable (6) | 0 | NT | 0 | 0 | 0 | — | ||||||
| 24 | Moderate | Stable (12) | E | E(1) | E(1) | 0 | E(1) | — | ||||||
| 25§ | Moderate | Stable (3) | 0 | 0 | NT | NT | NT | — | ||||||
| 26 | Moderate | Stable (12) | 0 | 0 | NT | 0 | 0 | — | ||||||
. | Change in T2 burden of disease-blinded analyses . | . | Serial clinical assessment for new or enhancing lesions . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Baseline* . | Last follow-up (mo) . | Baseline† . | 1 mo‡ . | 3 mo . | 6 mo . | 12 mo . | 24 mo . | ||||||
| 1 | Severe | Stable (24) | 0 | NT | 0 | 0 | 0 | 0 | ||||||
| 2 | Mild | Stable (24) | 0 | NT | 0 | 0 | 0 | 0 | ||||||
| 3 | Mild | Stable (24) | 0 | NT | 0 | 0 | 0 | 0 | ||||||
| 4 | Moderate | Decreased (24) | E | E(2) | 0 | 0 | 0 | 0 | ||||||
| 5 | Mild | Stable (12) | E | 0 | 0 | 0 | 0 | NT | ||||||
| 6 | Moderate | Decreased (24) | E | 0 | 0 | 0 | E(1) | 0 | ||||||
| 7 | Moderate | Stable (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 8§ | Moderate | Stable (12) | 0 | 0 | 0 | NT | 0 | NT | ||||||
| 9∥ | ||||||||||||||
| 10 | Mild | Stable (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 11 | Moderate | Decreased (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 12 | Moderate | Stable (24) | E | 0 | E(1) | E(1) | 0 | 0 | ||||||
| 13 | Moderate | Stable (24) | 0 | NT | 0 | 0 | 0 | 0 | ||||||
| 14 | Mild | Decreased (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 15¶ | Mild | Stable (12) | 0 | 0 | 0 | 0 | 0 | NT | ||||||
| 16∥ | Moderate | Stable (12) | 0 | NT | 0 | NT | 0 | NT | ||||||
| 17 | Severe | Decreased (24) | 0 | 0 | 0 | NT | 0 | 0 | ||||||
| 18 | Moderate | Stable (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 19 | Moderate | Decreased (24) | E | 0 | NT | 0 | 0 | 0 | ||||||
| 20 | Mild | Increased (24) | E | 0 | 0 | 0 | 0 | 0 | ||||||
| 21 | Moderate | Stable (24) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| 22 | Mild | Decreased (12) | 0 | 0 | 0 | 0 | 0 | — | ||||||
| 23 | Mild | Stable (6) | 0 | NT | 0 | 0 | 0 | — | ||||||
| 24 | Moderate | Stable (12) | E | E(1) | E(1) | 0 | E(1) | — | ||||||
| 25§ | Moderate | Stable (3) | 0 | 0 | NT | NT | NT | — | ||||||
| 26 | Moderate | Stable (12) | 0 | 0 | NT | 0 | 0 | — | ||||||
NT indicates not tested; E, enhancing lesions (number of lesions); and —, patients with less than 24 months of follow-up.
Mild indicates few scattered punctate lesions numbering 10 or fewer with none being greater than 10 mm in size. Moderate indicates larger number of punctate lesions numbering greater than 10 with some confluent lesions or individual lesions measuring greater than 10 mm in size. Total lesion burden measures up to 20% of cerebral white matter volume. Severe indicates extensive white matter involvement with T2 hyperintensity measuring between 20% and 50% of cerebral white matter volume.
Presence or absence of enhancing lesions; T2 burden of disease at baseline estimated in blinded analyses. Assessment after HDIT was to determine new (or larger) or enhancing lesions; E indicates enhancing lesions (number of lesions), and 0, no enhancing or new lesions.
After new lesions were noted at 1 month related to flare of MS during G-CSF mobilization, patients were scheduled for routine MRI brain at 1 month. No new nonenhancing lesions were noted in posttransplantation follow-up, so all new lesions were indicated as enhancing (and the number enhancing).
Lost to follow-up.
Death.
MRI brain deferred to 30 months because of head injury after fall at 24 months; CT scan of brain after fall did not show any changes and the patient remained clinically stable.